KPIs & Operating Metrics(New)
Breakdown Of AssetsCollaborative Agreement Revenue BreakdownCollaborative Agreement Revenue Breakdown AnnualCommercial Revenue By CategoryCommercial Revenue By Category AnnualContractual Obligations AnnualContractual Obligations TotalCost Of SalesDeferred RevenueEmployee StatisticsGross Margin %Gross ProfitIncome (Loss) Before Income TaxNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of Total Revenue %OPEX SegregationProperty, Plant And Equipment, Net BreakdownRaw Materials By SegmentR&D Revenue By CategoryR&D Revenue By Category AnnualR&D Revenue By Category (Deprecated)Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Gross Profit: 2009-2025

Historic Gross Profit for Ionis Pharmaceuticals (IONS) over the last 17 years, with Sep 2025 value amounting to $154.4 million.

  • Ionis Pharmaceuticals' Gross Profit rose 16.30% to $154.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $781.1 million, marking a year-over-year decrease of 1.45%. This contributed to the annual value of $693.9 million for FY2024, which is 10.87% down from last year.
  • As of Q3 2025, Ionis Pharmaceuticals' Gross Profit stood at $154.4 million, which was down 43.63% from $273.8 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Gross Profit ranged from a high of $437.8 million in Q4 2021 and a low of $109.0 million during Q1 2021.
  • Over the past 3 years, Ionis Pharmaceuticals' median Gross Profit value was $154.4 million (recorded in 2025), while the average stood at $184.6 million.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Gross Profit soared by 1,129.40% in 2021, and later slumped by 66.15% in 2022.
  • Ionis Pharmaceuticals' Gross Profit (Quarterly) stood at $437.8 million in 2021, then plummeted by 66.15% to $148.2 million in 2022, then skyrocketed by 116.89% to $321.4 million in 2023, then slumped by 30.70% to $222.7 million in 2024, then increased by 16.30% to $154.4 million in 2025.
  • Its last three reported values are $154.4 million in Q3 2025, $273.8 million for Q2 2025, and $130.1 million during Q1 2025.